Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHELE SARTORI

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1720078181
CMS profile
305058
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$68,007.56

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHELE SARTORI

NPI 1720078181 · CMS profile ID 305058

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720078181?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHELE SARTORI, NPI 1720078181, CMS profile ID 305058. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720078181?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHELE SARTORI, NPI 1720078181, CMS profile ID 305058. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720078181?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHELE SARTORI, NPI 1720078181, CMS profile ID 305058, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1720078181?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $68,007.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–129 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $304.8804/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189167961 CMS
Actelion Pharmaceuticals US, Inc. $27.9104/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174300326 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.4403/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225770788 CMS
AstraZeneca Pharmaceuticals LP $25.6203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206797140 CMS
Novo Nordisk Inc $365.8703/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188305886 CMS
Novo Nordisk Inc $117.3603/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188359818 CMS
Novo Nordisk Inc $6,868.7503/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188961450 CMS
Novo Nordisk Inc $772.7303/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189115447 CMS
Esperion Therapeutics, Inc. $17.1903/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243974334 CMS
Novo Nordisk Inc $9,969.5003/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1188402651 CMS
Novo Nordisk Inc $691.8603/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188535358 CMS
Novo Nordisk Inc $399.3803/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188700330 CMS
Novo Nordisk Inc $298.3003/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188795031 CMS
Novo Nordisk Inc $170.6703/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1188997277 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.1703/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222987046 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.3602/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225770785 CMS
Merck Sharp & Dohme LLC $21.6802/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238320792 CMS
ABIOMED $8.9002/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1175011619 CMS
ABIOMED $148.9702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175014673 CMS
ABIOMED $101.8302/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175015048 CMS
ABIOMED $36.6402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175017270 CMS
Abbott Laboratories $128.6402/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241051439 CMS
ABIOMED $111.8502/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175004949 CMS
Novartis Pharmaceuticals Corporation $38.6202/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200532092 CMS
Abbott Laboratories $185.0402/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241035835 CMS
Amgen Inc. $19.3601/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228644711 CMS
SCPHARMACEUTICALS INC. $24.7401/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228173696 CMS
AGEPHA Pharma FZ LLC $13.5701/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1178784455 CMS
Merck Sharp & Dohme LLC $18.0601/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238092497 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $24,377.10 195
PY2020 $3,974.38 68
PY2021 $44,737.25 139
PY2022 $18,983.74 116
PY2023 $45,982.94 126
PY2024 $60,060.53 105
PY2025 $68,007.56 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $121,648.00 15
PY2024 Principal investigator $215,495.96 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $738.00 12/12/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277893
Principal investigator 1 Janssen Research & Development, LLC $7,342.00 11/19/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277736
Principal investigator 1 Janssen Research & Development, LLC $8,867.00 11/07/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277830
Principal investigator 1 Janssen Research & Development, LLC $621.00 11/03/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277710
Principal investigator 1 Janssen Research & Development, LLC $3,328.00 09/19/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277775
Principal investigator 1 Janssen Research & Development, LLC $8,916.00 08/25/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277665
Principal investigator 1 Janssen Research & Development, LLC $6,889.00 07/23/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277916
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 06/23/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277703
Principal investigator 1 Janssen Research & Development, LLC $5,096.00 06/20/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277761
Principal investigator 1 Janssen Research & Development, LLC $10,369.00 05/23/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175277671
Principal investigator 1 Janssen Research & Development, LLC $8,906.00 05/21/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277798
Principal investigator 1 Janssen Research & Development, LLC $10,786.00 04/23/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277631
Principal investigator 1 Janssen Research & Development, LLC $6,471.00 03/21/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277768
Principal investigator 1 Janssen Research & Development, LLC $22,665.00 02/19/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277752
Principal investigator 1 Janssen Research & Development, LLC $17,828.00 01/22/2025 Non-covered Recipient Entity
Novel Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175277909